• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Progress Analysis of Top 7 Cancer Indications, Including Players, Drugs, Clinical Progress and Pitfalls

Posted on: Friday, 9 February 2007, 09:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c50146) has announced the addition of Top 7 Cancer Indications - Therapeutic & Competitive Insights to their offering.

With our 750 page report entitled "Top 7 Cancer Indications - Therapeutic & Competitive Insights" we present one of the largest reports published evaluating therapeutic and competitive insights in the anti-cancer arena. The report is structured according to the top 7 cancer indications: Breast cancer, Colon/colorectal cancer, Leukemia, Lung cancer, Lymphoma, Melanoma, and Prostate cancer.

No other report will provide a likewise structure and analysis. The report not only provides a close to complete structure of each cancer indication field, it as well describes the progress of hundreds of drugs in development. Information on most company related activities are included. More than 250 companies are involved in developing new drugs within the top seven cancer indications.

In the report the author does not only describe and analyze the latest years of progress but as we well provide an insight and framework to understand the complex field of cancer therapeutics. The report provides one of the most comprehensive coverage of the R&D trends to set the future marketplace. The author presents both an overview and a detailed description on the progress of key drugs in Phase II and III development, together with general descriptions on drugs and targets. In total we have selected more than 360 drug candidates to analyze. Among these drugs we clearly see substantial progress while others have failed. There will be a more intense competition in this market and current treatments will be changed for the benefit of more innovative therapies.

Scope of this report:

Progress analysis of Top 7 Cancer Indications, including players, drugs, clinical progress and pitfalls

-Breast Cancer

-Colon/colorectal cancer

-Leukemia

-Lung cancer

-Lymphoma

-Melanoma

-Prostate Cancer

Includes more than 250 drug developing companies

Includes more than 360 candidate drugs

The report includes more than 160 Tables, 200 Boxes and 600 high quality references

Key reasons to read this report:

- Understand the clinical and strategic challenges to the commercialization of drugs within the top 7 cancer indications

- Assess opportunities and risks for the continued development of drugs in seven major cancer indications

- Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development

TOP 7 CANCER INDICATIONS

THERAPEUTIC & COMPETITIVE INSIGHTS

1 EXECUTIVE SUMMARY

2 TABLE OF CONTENTS

21 LIST BOXES

22 LIST OF FIGURES

23 LIST TABLES

3 METHODOLOGY

4 LUNG CANCER

41 INTRODUCTION

42 CURRENT TREATMENT STRATEGIES

43 PROGRESS IN CURRENT TREATMENT STRATEGIES

44 KEY DRUG STRATEGIES IN LUNG CANCER

45 COMPETITIVE LANDSCAPE IN DRUG DEVELOPMENT: THE LATE STAGE PIPELINE

46 PROGRESS PROFILES ON APPROVED DRUGS

5 COLON CANCER

51 INTRODUCTION

52 CURRENT TREATMENT STRATEGIES

53 PROGRESS IN CURRENT TREATMENT STRATEGIES

54 KEY DRUG STRATEGIES IN CRC

55 COMPETITIVE LANDSCAPE IN CRC DRUG DEVELOPMENT

56 CURRENT CRC DRUG DEVELOPMENT

57 NECROTIC CELL DEATH INDUCERS

58 VACCINES: A HIGH THRESHOLD TO SUCCESS

59 IMMUNO-MODULATORS

510 ONCOLYTIC VIROTHERAPY IN CRC -- A TEAM OF FOUR

6 PROSTATE CANCER

61 INTRODUCTION

62 CURRENT TREATMENT STRATEGIES

63 PROGRESS IN CURRENT TREATMENT STRATEGIES

64 KEY THERAPEUTIC STRATEGIES FOR FUTURE THERAPIES

65 COMPETITIVE LANDSCAPE IN DRUG DEVELOPMENT: THE LATE STAGE PIPELINE

66 CURRENT DRUG DEVELOPMENT: THE EARLY STAGE PIPELINE

7 BREAST CANCER

71 INTRODUCTION

72 PROGRESS IN CURRENT TREATMENT STRATEGIES

73 COMPETITIVE LANDSCAPE IN DRUG DEVELOPMENT: THE LATE STAGE PIPELINE

74 CURRENT DRUG DEVELOPMENT: THE EARLY STAGE PIPELINE

75 APPENDIX B NEAR TERM "BREAST CANCER" PROGRESS

8 MELANOMAS

81 INTRODUCTION

82 CURRENT TREATMENT STRATEGIES

83 PROGRESS IN CURRENT TREATMENT STRATEGIES

84 CYTOTOXIC DRUGS

85 BIOLOGICAL TREATMENTS

86 COMPETITIVE LANSCAPE IN DRUG DEVELOPMENT: THE LATE STAGE PIPELINE

87 KEY THERAPY STRATEGIES

88 CURRENT DRUG DEVELOPMENT: THE EARLY STAGE PIPELINE

9 THE LYMPHOMAS

91 INTRODUCTION

92 CURRENT TREATMENT STRATEGIES

93 PROGRESS IN CURRENT TREATMENT STRATEGIES

94 KEY THERAPEUTIC STRATEGIES FOR FUTURE TREATMENTS

95 COMPETITIVE LANDSCAPE IN DRUG DEVELOPMENT: THE LATE STAGE PIPELINE

96 CURRENT DRUG DEVELOPMENT: THE EARLY STAGE PIPELINE

10 THE LEUKEMIAS

101 INTRODUCTION

102 CURRENT TREATMENT STRATEGIES

103 PROGRESS IN CURRENT TREATMENT STRATEGIES

104 KEY THERAPEUTIC STRATEGIES FOR FUTURE THERAPIES

105 COMPETITIVE LANDSCAPE IN DRUG DEVELOPMENT: THE LATE STAGE PIPELINE

106 CURRENT DRUG DEVELOPMENT: THE EARLY STAGE PIPELINE

107 DRUGS APPROVED FOR THE TREATMENT OF LEUKEMIA: A HISTORICAL PERSPECTIVE

11 DISCLAIMER

111 LIABILITY

112 COMPLETENESS

12 DRUG INDEX

13 COMPANY INDEX

21 List Boxes

22 List of Figures

23 List Tables

Some of the Companies mentioned inside this report include:

- Amgen

- Chugai

- Coley Pharmaceuticals

- Cytokinetics

- Genentech

- GlaxoSmithKline

- Hayashibara

- Hoffmann La Roche

- Novartis

- OSI

- Pfizer

- Roche

- Sanofi-Aventis

- Schering-Plough

- Wyeth

For more information visit http://www.researchandmarkets.com/reports/c50146

Source: Business Wire

More News in this Category